Plum SEC
  • Korean Market
  • Privacy Policy

Korean Market

  • Reset (View All)

  • ★★★★★
  • ★★★★
  • ★★★
  • ★★
  • ★

  • ★

  • ★
  • ★★
  • ★★★
  • ★★★★
  • ★★★★★
All Disclosures
EXCH
KANGSTEM BIOTECH
★

Investor Relations Event to Enhance Understanding: Updates on Knee Osteoarthritis Drug OSCA Clinical Trials and Organoid Business

  06/02/2026, 09:57 AM
PERI
KANGSTEM BIOTECH
★

Kangstem Biotech Q1 2026: Sales decline, operating loss improves; OSCA license deal with Yuyoung Pharma ongoing

  05/14/2026, 04:19 PM
한국어 | English | 中文 | 日本語
Plum SEC © 2026.05.25
The information provided on this site is for reference only and we do not guarantee its accuracy or completeness. Users are solely responsible for any investment decisions made based on this information.